Document:

<PAGE>

                                                                   Exhibit 10.57

                          LICENSE AND SUPPLY AGREEMENT

This License and Supply Agreement (the "Agreement") is entered into as of
November 12,2002, by and between Shaklee Corporation, a Delaware corporation,
with its principal place of business at 4747 Willow Road, Pleasanton, California
94588 ("Shaklee") and Senetek PLC, a company formed and existing under the laws
of the United Kingdom, with its principal place of business at 620 Airpark Road,
Napa, California 94558 ("Senetek").

                                    RECITALS

Whereas, Senetek has patents covering the use of kinetin compound in skin care
and cosmetic products and is the owner of related technology; and

Whereas, Senetek is the owner of the formula and technology for a product known
as Eye Gel (Product #42-440); and

Whereas, Shaklee wishes to be granted the right to incorporate kinetin compound
in certain of its skin care products and to have Senetek supply kinetin compound
for such purpose; and

Whereas, in addition to formulating kinetin-based products into Shaklee
formulations, Shaklee wishes to license Senetek's formula for Eye Gel and to
have Senetek manufacture this Product for Shaklee;

Now, therefore, in consideration of the mutual promises, covenants and
conditions set forth in this Agreement, Shaklee and Senetek agree as follows:

1.  DEFINITIONS.

          a.   Affiliate. The term "Affiliate" shall mean, with respect to any
               person or entity, any person or entity controlling, controlled
               by, or under common control of or with such person or entity.
               Control shall mean the ownership or control, directly or
               indirectly of fifty percent (50%) or more of the voting stock of
               the company or the ability to control, through whatever means,
               the governing body of such entity.

          b.   Authorized Channel. The term "Authorized Channel" means the
               multi-level marketing channels, catalog sales, and the Internet.

          c.   Kinetin. The term "kinetin" shall mean the cytokinin compound
               described by the international identifier CAS #525-79-1.

          d.   Cost. The term "Cost" means Senetek's cost of supplying kinetin
               compound and transferring the kinetin technology to Shaklee,
               including Senetek's cost of direct labor of employees while
               directly employed in the supplying of kinetin compound and
               transfer of kinetin technology; direct materials and components,
               calculated direct energy, utilities and other charges incurred
               directly in the manufacture and supply of kinetin and transfer of
               kinetin technology.

          e.   Eye Gel. The term "Eye Gel" means Senetek Product #42-440.

<PAGE>

Confidential Treatment Requested
--------------------------------

          f.   Products. The term "Products" shall mean those Products
               manufactured for or by Shaklee and/or sold by Shaklee to which
               kinetin will be added per the conditions of this Agreement. This
               Agreement explicitly includes the following Products;
                  Enfuselle Time Repair AM SPF 15 (Shaklee Product)
                  Enfuselle C + E Repair PM (Shaklee Product)

          g.   Future Products. The term "Future Products" shall mean any
               additional kinetin-based products which are jointly envisioned by
               Shaklee and Senetek and which may be added to this Agreement via
               an Addendum for each new product on a case-by-case basis.

          h.   Finished Products. The term "Finished Products" shall mean
               Shaklee Products manufactured to include the compound, kinetin.

          i.   Patent. The term "Patent" shall mean the Senetek patents (set
               forth in Schedule A) relating to the proprietary kinetin-based
               compositions and related technology sold by Senetek under the
               U.S. brand name, Kinetin.

          j.   Technology. The term "Technology" means all valuable data and
               information, including without limitation the formula,
               specifications, clinical study data, and safety information,
               which are necessary or useful for the manufacture of the Finished
               Products.

          k.   Territory. The term "Territory" means all countries of the world.

2.  TERM OF AGREEMENT.

The term of this Agreement shall be five (5) years from the date set forth
above, unless it is terminated earlier by either Party for default or other
event giving rise to a right of termination as described in Section 13, below.

3.  GRANT OF LICENSE.

          a.   Senetek hereby grants to Shaklee a nonexclusive license under the
               Patents held by Senetek to incorporate kinetin compound in the
               range of [***] as an ingredient in the Finished Products, and a
               nonexclusive license to use and sell the Finished Products within
               the Authorized Channel in the Territory. Senetek also grants to
               Shaklee an exclusive license to the Eye Gel (Senetek product
               #42-440) within the Authorized Channel in the Territory.

          b.   Transfer of Technology. Senetek shall furnish Shaklee with one
               copy of all Technology, including but not limited to know how,
               [***], clinical testing data, process sheets, raw material and
               process specifications, formulas, manuals, and other writings and
               any software with respect to the Eye Gel and incorporation of
               kinetin in the Products, which may reasonably be required by
               Shaklee to manufacture, package, and commercialize the Finished
               Products and Eye Gel.

          c.   Patent Enforceability. In consideration of the benefits of this
               Section 3, Shaklee, for itself and its Affiliates, successors and
               permitted assigns and sub- licensees, irrevocably acknowledges,
               admits and concedes that (i) all rights, title and interest in
               the Patent is owned by Senetek and its Affiliates, (ii) all
               claims of the Patent as well as all claims that are narrower in
               scope than the claims of the Patent are valid and enforceable,
               and (iii) all claims of any patent that may issue from any
               application whose subject matter in whole or in part is entitled
               to the benefit

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>
Confidential Treatment Requested
--------------------------------

               of the filing date(s) of the Patent (including, without
               limitation, continuations, continuations-in-part, divisional
               patents, reexaminations, renewals, extensions, reissues, and
               foreign counterparts) that are equal to or narrower in scope than
               the claims of the Patent are valid and enforceable. Shaklee, for
               itself and its Affiliates, successors and permitted assigns and
               sub-licensees, does also forever relinquish and waive all rights
               to dispute said ownership, validity and enforceability in any
               proceeding of any nature, covenants that it and they will not
               assert, either affirmatively or defensively, in any proceeding of
               any nature, any matter inconsistent with said ownership, validity
               and enforceability, agrees and acknowledges that the foregoing
               shall act as a complete defense and bar to any proceeding of any
               nature challenging such ownership, validity and enforceability or
               any of them, and consents to the entry of temporary and permanent
               injunctions to bar any breach or threatened breach of any of the
               foregoing, without the filing on behalf of Senetek of any bond or
               other security.

          d.   Promotion of the Products. Shaklee agrees that in marketing and
               selling Finished Products it shall not advertise the
               concentration of kinetin in the Product(s) nor will it make any
               comparative claims of product benefit to those kinetin-containing
               products of Senetek or other Senetek licensees, the current list
               of licensees being identified in Exhibit B, hereto attached. In
               addition, with regard to statements of product benefit and/or
               safety that relate to the kinetin ingredient, Shaklee will submit
               to Senetek the text of such statements for Senetek prior
               approval, and such approval by Senetek will not be unreasonably
               withheld or delayed. Shaklee may include in packaging, labeling
               and/or promotional materials for the Finished Products and/or Eye
               Gel that they contain kinetin and may also include the following
               or a similar statement presented in a manner consistent with
               industry practice: "Manufactured and sold under license from
               Senetek". Shaklee may further include the Senetek patent numbers
               relevant to the kinetin technology as described in this
               Agreement.

          e.   Other Rights. It is expressly understood that this Agreement
               grants no rights to Shaklee with respect to any intellectual
               property or confidential information of Senetek except those
               express rights set forth in Section 3.

4.  SUPPLY OF THE KINETIN.

          a.   Senetek covenants that the kinetin compound supplied to Shaklee
               pursuant hereto shall be manufactured in accordance with all
               relevant legal and regulatory requirements, that the manufacturer
               of such compound shall conduct all appropriate quality control
               and related testing to insure that the compound is fit for use in
               human skin care products. Senetek shall provide to Shaklee upon
               request and at no cost to Shaklee, with respect to each
               manufacturing batch of kinetin, proof of ingredients used in the
               manufacture of the kinetin with a certificate of analysis for
               such compound. Upon reasonable notice, Senetek shall permit
               representatives of Shaklee to observe all quality control testing
               and inspect all quality control documentation related to the
               kinetin supplied by Senetek to Shaklee. Senetek further covenants
               that such kinetin compound meets the current Senetek
               specifications [***].

          b.   Skin permeation testing for each new kinetin-based Product will
               be conducted under the supervision and with the established
               methods of Senetek (to ensure that the kinetin active material is
               properly delivered to the skin). Shaklee will pay for the skin
               permeation testing as it applies to the Shaklee formulations
               (i.e., Enfuselle Time Repair AM SPF 15 and Enfuselle C+E Repair
               PM), and Senetek will pay for skin permeation testing as it
               applies to the Eye Gel.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>
Confidential Treatment Requested
--------------------------------

          c.   Senetek will supply the kinetin compound to Shaklee in accordance
               with Shaklee Purchase Orders, which shall set forth the quantity
               and delivery terms, within ninety days of receipt of Shaklee's
               Purchase Order. Senetek shall ensure that the kinetin is properly
               packed and marked for shipping and routed in accordance with
               Shaklee's Purchase Order. Shipping terms shall be F.O.B.
               Senetek's shipping dock, with freight paid by Shaklee collect. In
               the event of any conflict between the terms of a Shaklee Purchase
               Order and this Agreement, the terms of this Agreement shall
               govern, unless otherwise expressly agreed to in writing and
               signed by both parties.

          d.   If the kinetin or any portion thereof delivered by Senetek to
               Shaklee is defective in any respect at point of delivery to
               Shaklee's carrier, Shaklee may retain all or any portion of the
               kinetin delivered and return the balance of the defective kinetin
               to Senetek at Senetek's sole expense. Shaklee may require, at its
               option, that Senetek replace any kinetin that Shaklee is entitled
               to reject or grant a refund or credit to Shaklee in lieu thereof.
               Shaklee shall provide notice of rejection of defective kinetin to
               Senetek within 90 days of receipt of the kinetin. Acceptance of
               the kinetin shall be subject to revocation upon later discovery
               of any latent defect in the kinetin at the point of delivery to
               Shaklee's carrier. In the event of a dispute as to whether the
               kinetin is defective, samples of the production lot(s) in dispute
               shall be sent to a testing laboratory mutually agreed to by
               Senetek and Shaklee, whose findings shall be binding on the
               Parties. The cost of such testing shall be borne by the Party
               whose position is not upheld by the testing laboratory. The final
               decision whether to release a production lot of Finished Product
               shall remain with Shaklee. In the case that Senetek provides bulk
               Eye Gel product to Shaklee, Shaklee will prepare the final
               packaging and will decide whether to release a production lot of
               the final Eye Gel finished product. In the case whereby Senetek
               manufactures the Eye Gel complete with final packaging, the
               decision to release production lots of Eye Gel will remain with
               Senetek (based on mutually agreed upon specifications for the Eye
               Gel).

5.  MANUFACTURING OF EYE GEL BY SENETEK.

Senetek will provide manufactured Eye Gel containing kinetin to Shaklee for the
price of [***] per unit based on a lot size of [***] units; these units will be
bulk packed and either shipped to Shaklee for final packaging, or, if requested
by Shaklee, placed into final packaging at Senetek's manufacturer (the cost of
such final packaging will be borne by Shaklee). The manufacturing costs detailed
in this Section 5 are in addition to the Royalty payments indicated in
Section 8.

6.  COMPLIANCE WITH LAWS.

Shaklee and Senetek shall comply with all laws, regulations, ordinances, orders,
injunctions, decrees and requirements applicable to the manufacturing,
packaging, storage, shipment and export of all products manufactured pursuant to
the license granted herein, and to its marketing and sale of such products.
Without limiting the foregoing, Shaklee shall manufacture the Finished Products
and Senetek shall manufacture the Eye Gel in full compliance with all applicable
good manufacturing practices requirements for the Territory, shall conduct
appropriate stability testing of such products, shall maintain and implement
appropriate quality control and quality assurance procedures for all raw
materials and components, whether produced internally or supplied by vendors,
and all bulks, work in process and finished goods, shall package, label and
advertise such products marketed and sold by it in accordance with all
applicable legal requirements and in a manner not infringing or violating any
intellectual property or trade rights of third persons, and obtain and maintain
all marketing approvals, registrations or other permits necessary for the lawful
manufacture, packaging, storage, shipment and export, and for its marketing and
sale of such products, in the Authorized Channel within the Territory.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

Confidential Treatment Requested
--------------------------------

7.  RECALLS.

In the event any Product(s) manufactured and/or sold by Shaklee pursuant to this
Agreement must be recalled from distribution by reason of failure to meet any
requirements of law or otherwise, Shaklee shall have the sole responsibility to
conduct the activities necessary for such a recall, with the reasonable
assistance of Senetek to the extent necessary and requested. The costs of such
recall shall be borne by Senetek if arising from the supply of defective Eye Gel
and otherwise by Shaklee.

8.  ROYALTY AND PAYMENT.

          a.   Shaklee shall pay to Senetek a royalty for each unit of the
               Finished Products and/or the Eye Gel sold by Shaklee, as follows:

                    U.S. [***] per unit for each unit sold by Shaklee in any
                    calendar year up to [***] units;

                    U.S. [***] per unit for each unit sold by Shaklee in any
                    calendar year in excess of [***] up to and including
                    [***]; and

                    U.S. [***] per unit for each unit sold by Shaklee in any
                    calendar year in excess of [***] units.

          b.   Senetek further agrees in consideration of work conducted by
               Shaklee on the formulation of kinetin-based formulations, to
               provide a one-time credit to Shaklee of [***] per unit for the
               first [***] units sold by Shaklee under this Agreement.

          c.   Senetek shall supply Shaklee with Kinetin compound at Senetek's
               Cost, which is currently at [***] per kilogram.

          d.   Senetek shall transfer the kinetin Technology necessary for
               Shaklee to manufacture and/or commercialize the Finished Products
               at Senetek's Cost.

          e.   Senetek shall invoice Shaklee for the Cost of the kinetin
               compound supplied, and Shaklee shall pay such invoices within
               thirty (30) days of receipt.

          f.   Within thirty (30) days after the end of each calendar quarter,
               Shaklee shall send to Senetek a written accounting reporting the
               number of units of Finished Products and Eye Gel sold during such
               calendar quarter and, at the same time, shall pay the royalty set
               forth in subsection (a) above. A handling charge of 1.5% per
               month shall be assessed on any payments more than thirty (30)
               days past due.

9.  RECORDS/INFRINGEMENT/RECOVERY.

          a.   Books and Records. Shaklee shall maintain books and records in
               accordance with generally accepted accounting and good
               manufacturing practices standards reflecting all amounts included
               in its calculation of royalty payable pursuant to Section 8, and
               shall provide Senetek reasonable access, with at least (10) days
               prior notice and at times not unreasonably disruptive of
               Shaklee's operations, to conduct audits thereof. No more than one
               such audit shall be conducted during any twelve (12) month period
               unless an audit documents a

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

Confidential Treatment Requested
--------------------------------

               deficiency in royalties due of more than ten (10) percent, in
               which event audits may be conducted semi-annually thereafter
               until such audits fail to document such a deficiency. Shaklee
               shall pay a handling charge of one-and-one-half (1-1/2) percent
               per month on the amount of any deficiency in royalties paid
               determined as a result of any such audit. The costs of any such
               audit shall be borne by Senetek unless such audit documents a
               deficiency of more than ten (10) percent, in which case such
               costs shall be reimbursed by Shaklee.

          b.   Notification of Infringement. During the Term, each party shall
               promptly advise the other in writing of any infringement,
               imitation or act by third parties inconsistent with the ownership
               of and rights of Senetek to the Patent or any act of unfair
               competition by third parties with respect to the Finished
               Products or the Eye Gel (any of the foregoing shall be referred
               to as an "infringement") wherever and whenever such infringement
               or act shall come to the attention of such party. If such
               infringement occurs within the Territory, Senetek shall promptly
               take such commercially reasonable action as is required to
               restrain such infringement or otherwise enforce its rights and
               Shaklee shall cooperate fully with the Senetek in such action
               and, if so requested, shall join with Senetek as a party to any
               appropriate legal proceedings for such purpose. Senetek shall
               bear all expenses in connection with the foregoing. In the event
               that within a reasonable time after Senetek becomes aware of such
               infringement within the Territory, Senetek fails to take
               appropriate and diligent action with respect to such
               infringement, Shaklee shall have the right, to the extent
               permitted by law, to institute an action for infringement at its
               own expense, and in its own name, or in the name of any of its
               Affiliates and the right to enforce and collect any judgment
               thereon, subject to the following paragraph.

          c.   Recovery. Any recovery by either party as a result of any claim,
               demand, litigation or other action contemplated by clause b.
               above or any settlement thereof shall first be used to reimburse
               each party for the reasonable costs of the action borne by such
               party (or, if the recovery is less than the aggregate costs of
               such action, shall be distributed between the parties in
               proportion to the costs of the action borne by each of the
               parties), with the remaining amount, if any, to be paid to
               Senetek.

10. INSURANCE/RISK OF LOSS/INDEMNIFICATION.

          a.   Insurance. During the term of this Agreement, Senetek and Shaklee
               shall each maintain at their own cost and expense, commercial
               general liability insurance including coverage for
               products/completed operations with annual limits of liability in
               an amount not less than [***] per occurrence, [***] general
               aggregate; and [***] products/completed operations aggregate, and
               Shaklee shall maintain at its own cost and expense insurance of
               not less than [***] per occurrence, [***] aggregate, covering the
               selling price value of Finished Products and the Eye Gel in its
               possession or control, in each case with an insurance company
               having a current A.M. Best rating of B+ or better. The insurance
               of each Party shall name the other Party as an additional insured
               under the Broad Form Vendor Endorsement. The insurance shall be
               primary to and non-contributory with any insurance maintained by
               the other Party.

          b.   Interruption. During the term of this Agreement Senetek shall
               notify Shaklee in writing within 24 hours, or as soon as
               practicable, of a major business interruption and/or a natural
               catastrophe that may prevent or delay the delivery of kinetin
               substance or Eye Gel to Shaklee, and Shaklee shall notify Senetek
               in writing within 24 hours, or as soon as practicable, of a major
               business interruption and/or a natural catastrophe that may
               prevent or delay the receipt of kinetin compound or Eye Gel from
               Senetek.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

          c.   Loss. All risk of loss or damage to the kinetin compound from any
               cause whatsoever shall be borne by Senetek until delivery of the
               kinetin compound to, and receipt of the shipment by, Shaklee's
               carrier.

          d.   Indemnification by Senetek. Senetek shall indemnify Shaklee,
               defend and hold Shaklee and Shaklee's officers, directors,
               employees and agents harmless from any and all liability, damage,
               loss, costs or expenses, including reasonable attorneys' fees,
               resulting from claims made by any person in connection with the
               use of the kinetin compound, Eye Gel, and/or Finished Products to
               the extent such claims arise out of the negligence, willful
               misconduct of, or breach of any of the terms of this Agreement
               by, of Senetek.

          e.   Indemnification by Shaklee. Shaklee shall indemnify Senetek,
               defend and hold Senetek's and Senetek's officers, directors,
               employees and agents harmless from any and all liability, damage,
               loss, costs or expenses, including reasonable attorneys' fees,
               resulting from claims made by any person in connection with the
               use of the kinetin compound, Eye Gel, and/or the Finished
               Products to the extent such claims arise out of the negligence,
               willful misconduct of, or breach of any of the terms of this
               Agreement by, of Shaklee.

          f.   Consequential Damages. Except for claims that include
               consequential damages paid to persons that are not Affiliates of
               an indemnified party, neither Party shall be liable to the other
               for consequential damages, lost profits, injury to reputation, or
               similar claims. Except for claims by third parties, and except as
               provided in Section 7 above relating to Recalls, under no
               circumstances shall Senetek or its Affiliates have any liability
               arising from this Agreement in excess of the highest aggregate
               amount paid to Senetek by Shaklee over the course of any two
               contract year periods.

11. WARRANTY.

Senetek warrants that the kinetin compound and Eye Gel supplied to Shaklee
pursuant to this Agreement, at the time it is delivered to and accepted by
Shaklee's carrier, will (i) be free from defects in manufacturing and materials;
(ii) shall not be adulterated under the meaning of the Federal Food, Drug, and
Cosmetic Act; (iii) shall be manufactured and packaged in a manner which
complies with applicable Food and Drug Administration regulations; and (iv)
shall be fit for use in human skin care products. Senetek further warrants that
the Eye Gel product has been clinically tested for safety and is fit for use as
a human skin care product. In addition, Shaklee warrants that the Finished
Products and the Eye Gel, at the time that they are sold by Shaklee or its
Affiliates, will, (i) conform to the warranties set forth in the preceding
sentence and (ii) shall be manufactured and packaged in a manner which complies
with the all regulatory requirements applicable in each respective country of
sale.

12. CONFIDENTIALITY.

Senetek and Shaklee have entered into a Mutual Nondisclosure Agreement ("MNDA ")
effective July 17, 2002, incorporated herein by reference. The provisions of
such MNDA shall apply to this Agreement and shall remain in full force and
effect during the Term of this Agreement and shall survive the expiration or
termination of this Agreement for a period of five (5) years after such
expiration or termination regardless of any expiration or termination provision
of such MNDA.

13. TERMINATION.

          a.   This Agreement may be terminated immediately by either Party in
               the case of a material

<PAGE>

               breach by the other Party of anyone or more of the terms of this
               Agreement which is not remedied within thirty (30) days after
               receipt by the breaching party of written notice of the breach as
               sent by the terminating Party, or if such breach cannot
               reasonably be cured within such thirty (30) day period, if the
               breaching party has failed to commence such cure within such
               period and diligently prosecute such cure to completion within a
               reasonable time thereafter;

          b.   This Agreement may also be terminated immediately by either Party
               if the other Party files a petition in bankruptcy or a petition
               in bankruptcy is filed against the other Party which is not
               vacated within sixty (60) days or the other Party becomes
               insolvent or makes an assignment for the benefit of creditors or
               any arrangement pursuant to any bankruptcy law;

          c.   This Agreement may be terminated by Shaklee for any or no reason,
               with or without cause, upon giving at least ninety (90) days
               prior written notice. Notwithstanding Shaklee's termination of
               the Agreement, it shall be responsible for payment and take
               delivery of any kinetin compound under a Shaklee Purchase Order
               in effect as of the date of notice of termination. Shaklee shall
               not be responsible for any other charges or damages in the event
               of termination pursuant to this paragraph.

14. FORCE MAJEURE.

Neither Party shall be liable for delay or failure in the performance of any of
its obligations under this Agreement if and to the extent such delay or failure
is due to circumstances beyond the reasonable control of such Party, including
but not limited to fires, floods, explosions, accidents, acts of God, war, riot,
strike, lockout or other concerted acts of workers, acts of government and
shortages of materials; provided, however, that the party claiming that "force
majeure" has affected its performance shall give notice to the other party
within ten (10) days of becoming aware of the occurrence of force majeure,
giving full particulars of the cause or event and the date of first occurrence
thereof, and provided, further, that no force majeure event shall affect
Shaklee's obligation to make timely payment of the cost of kinetin compound
supplied by Senetek or of the royalties due on sales of Finished Products. The
Party claiming force majeure shall use its best efforts to eliminate or prevent
the cause so as to continue performing its obligations under this Agreement.

15. NOTICES.

Any notice required or permitted to be given under this Agreement shall be in
writing and shall be given by sending such notice properly addressed to the
other Party's address shown below by prepaid registered or certified mail,
return receipt requested, or by overnight delivery service by the U.S. Post
Office or private carrier. All such notices shall be deemed given when received:

If to Shaklee:    Shaklee Corporation
                  1992 Alpine Way
                  Hayward, CA 94545
                  Attn: Jim Greene, Vice President, Product Development

                  With a copy to:
                  Shaklee Corporation
                  4747 Willow Road
                  Pleasanton, CA 94588
                  Attn: Marjorie L. Fine, Esq., General Counsel

If to Senetek:    Senetek PLC

<PAGE>

Confidential Treatment Requested
--------------------------------

                  620 Airpark Road Napa, CA 94558
                  Attn: [***]

16. INVENTIONS AND DISCOVERIES.

If during the Term of and/or as a direct result of this Agreement, either
Shaklee employees or agents or Senetek employees or agents conceive and/or
reduce to practice a discovery or invention, ownership of such discovery or
inventions shall be apportioned as follows:

          a.   If it relates to Senetek's proprietary materials or technology,
               and does not materially relate to Shaklee's proprietary materials
               or technology, it will be owned by Senetek.

          b.   If it relates to Shaklee's proprietary materials or technology,
               and does not materially relate to Senetek's proprietary materials
               or technology, it will be owned by Shaklee.

          c.   If it materially relates to both Senetek's proprietary materials
               or technology and to Shaklee's proprietary materials or
               technology, the parties agree to negotiate in good faith for the
               ownership, rights, use, reduction to practice and
               commercialization of the new technology, the details of which
               will contained in a development agreement between the parties.
               Both parties further agree that prior to a joint agreement
               covering such new technology, neither party will pursue the
               patenting, development or commercialization of such new
               technology without the express written permission of the other
               party.

Each party agrees to assign to the other all rights to all such inventions or
discoveries, consistent with the above-identified ownership rights, in the
Territory. Should Senetek or Shaklee decide to apply for patent protection on
any of such discoveries or inventions relating to materials, composition or
methods of use (as described and allocated immediately above), each party agrees
to assist the other, at the other's reasonable expense, to obtain patent
protection and to assign the patents to the other, including executing any
documents required. In the case of solely-owned inventions or discoveries, the
party that owns such inventions or discoveries shall, at its own expense, have
the right to apply for such patent protection and to prosecute applications for
patents through attorneys and agents of its own choosing.

17. ADDITIONAL PROVISIONS.

          a.   No Assignment. Neither Party may assign this Agreement without
               the prior written consent of the other Party hereto, which
               consent shall not be unreasonably withheld. Irrespective of the
               foregoing, either Party may assign this Agreement to an Affiliate
               in the event of a non-bankruptcy related internal reorganization
               of the corporate structure without the consent of the other
               Party.

          b.   Enforceability. The Parties hereto agree that this Agreement
               shall be legally binding upon them and their respective legal
               representatives, successors and assigns.

          c.   Entire Agreement. Except as provided in paragraph 12 of this
               Agreement, this Agreement contains the entire understanding of
               the Parties relating to the subject matter hereof, and supersedes
               all prior discussions and agreements between them, including but
               not limited to a Master Supply Agreement of November 6, 2001
               between Technica Consumer Health, a division of Shaklee
               Corporation, and Senetek, which is hereby cancelled. This
               Agreement may be modified only by an instrument in writing signed
               by both Parties.

          d.   Governing Law. This Agreement shall be governed by and
               interpreted in accordance with the

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

               laws of the State of California.

          e.   Waiver. A waiver of any term or condition of this Agreement in
               anyone instance shall not be deemed to continue to be a waiver of
               such term or condition for any similar instance in the future or
               of any subsequent breach hereof.

          f.   Announcements. The parties will issue an agreed upon press
               release upon the execution of this Agreement. Except for such
               release and except as may otherwise be required by law or the
               listing rules of any exchange on which either party's securities
               may be listed or quoted, for which the releasing party shall
               provide prior notice to the other party and the opportunity to
               comment on any required disclosure, neither party will disclose
               the terms of this Agreement to any other person; provided that
               each party may make such disclosure of the terms of this
               Agreement to its employees and agents as is necessary to permit
               such party to perform its obligations under this Agreement;
               provided that any such employee or agent agrees to maintain the
               confidentiality of this Agreement; and provided that at either
               party may make such disclosures of the terms of this Agreement as
               are necessary to enter into license and other agreements that do
               not conflict with the terms of this Agreement. Shaklee
               acknowledges that this Agreement may be deemed to be a "material
               contract" as that term is defined by Item 601(b)(l0) of
               Regulation S-K, and that Senetek may therefore be required to
               file such document as an exhibit to reports or registration
               statements filed under the United States Securities Act or
               Securities Exchange Act, provided that Senetek shall redact
               commercial terms and file for confidential treatment to the
               extent permitted by applicable rules of the United States
               Securities and Exchange Commission.

<PAGE>

IN WITNESS WHEREOF, the Parties hereto have read and executed this Agreement as
of the day and year first above written.

SENETEK PLC                                   SHAKLEE CORPORATION

By:                                           By:
/s/ J. Michael Delmage                        /s/ James A. Greene
----------------------------                  ------------------------------
J. Michael Delmage                            James A. Greene
Chief Technology Officer                      Vice President, R&D
Senetek, PLC                                  Shaklee Corporation<PAGE>

                                                                   Exhibit 10.58

                                LICENSE AGREEMENT

            This License Agreement (this "Agreement") is made and entered into
as of September 30, 2002, by and between Senetek PLC, a United Kingdom
corporation with offices located at 620 Airpark Road, Napa, California 94558
("Senetek"), and Vivier Pharma Inc., a Quebec corporation with a mailing address
at P.O Box 1282, Hudson, Quebec, Canada ("Vivier" and, together with Senetek,
the "Parties").

                                   BACKGROUND

            A.    Senetek has developed and holds certain patents and other
proprietary intellectual property relating to the use as a skin care or cosmetic
product of formulations containing Kinetin, and Vivier has developed and holds
certain patent applications and other proprietary intellectual property relating
to the use as a skin care or cosmetic product of a unique formulation of Vitamin
C (herinafter, "Vivier C").

            B.    Vivier desires to manufacture, market and sell in the
Authorized Channel within the Territory (both as defined below) skin care
products containing Kinetin in combination with Vivier C (hereinafter, "Kinetin
C").

            C.    Senetek desires to market and sell, and to license third
parties to market and sell, Vivier C and Kinetin C products.

            D.    Senetek is willing to grant Vivier the right to manufacture,
market and sell Kinetin C products in the Authorized Channel in the Territory
all as set forth in this Agreement, and Vivier is willing to manufacture and
supply to Senetek, and grant Senetek the right to market and sell, Vivier C and
Kinetin C products all as set forth in this Agreement.

            Accordingly, in consideration of the mutual promises, covenants, and
conditions set forth below, the Parties agree as follows:

1.    DEFINITIONS

            When used in this Agreement, each of the following capitalized
terms shall have the respective meanings set forth in this Article.

      1.1   "Affiliate" means any corporation, partnership, proprietorship or
other legal entity directly or indirectly controlled by, controlling, or under
common control with another legal entity, "control" meaning, for purposes
hereof, the effective power to elect at least a majority of the Board or
Directors or other management body of a legal entity or to effectively direct
the management of a legal entity, by the ownership of voting securities, by
contract, or otherwise.

<PAGE>

      1.2   "Agreement Date" means the date of this Agreement first set forth
above.

      1.3   "Authorized Channel" means the ethical market channel, including
dermatologists and other physicians and pharmacies, medical clinics, HMOs and
other recognized prescription drug channels in Canada, including wholesalers and
distributors re-selling to such channels.

      1.4   "Best Efforts" means that commercially reasonable degree of effort,
expertise, knowledge and resources which one skilled, able, familiar with and
experienced in the matters set forth herein would utilize and otherwise apply
with respect to fulfilling a like obligation subject to existing legal,
contractual and other restrictions.

      1.5   "Calendar Quarter" means a period beginning on the first day of
January,  April,  July or  October  and  ending on the last day of March,  June,
September, or December, respectively.

      1.6   "Confidential Information" means marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, businesses and operations of a party or its Affiliates
disclosed by such party to the other party or its Affiliates or of which the
other party or its Affiliates gains knowledge in performing this Agreement.
"Senetek Confidential Information" means Confidential Information of Senetek and
"Vivier Confidential Information" means Confidential Information of Vivier.

      1.7   "Contract Year" means a period beginning on any January 1 during the
Term and ending on the first to occur of December 31 of such calendar year or
the termination of this Agreement; provided, however, that the first Contract
Year shall commence on the Agreement date and end on December 31, 2003.

      1.8   "Documentation" means the documentation relating to the Patents and
Know-How identified in Schedule 1.8.

      1.9   "Final Adjudication" means any decision by a Governmental Entity of
competent jurisdiction if either (a) any and all appeals (including to other
Governmental Entities of competent jurisdiction) in connection with the
adjudication are exhausted or (b) the time for any such appeal shall have passed
without such appeal having been perfected.

      1.10  "Government Entity" means any competent governmental agency, board,
authority, commission, court or other governmental entity having lawful
jurisdiction.

      1.11  "Intellectual Property" means collectively the Patents, the
Know-How and such common law and statutory trademarks, trade names, copyrights,
designs and other proprietary rights related to or useful in the performance of
this Agreement as a party has or acquires during the Term of this Agreement to
the extent that the same is not subject to an agreement or commitment precluding
such party or its Affiliates from making it available to the other party.
"Senetek Intellectual Property" means the Senetek Patents, the Senetek Know-How
and the other proprietary rights not subject to such an agreement or commitment
that are related to Kinetin, and "Vivier Intellectual Property" means the Vivier
Patents, the Vivier Know-How and

                                        2

<PAGE>

Confidential Treatment Requested
--------------------------------

the other proprietary rights not subject to such an agreement or commitment that
are related to Vivier C.

      1.12  "Know-How" means such special knowledge, trade secrets and technical
or other proprietary information, whether or not patented or patentable, owned
or controlled by a party or its Affiliates at any time prior to or during the
term of this Agreement specifically related to the development, manufacture or
use of the Products or Vivier C to the extent that such special knowledge,
technical or other information is not subject to an agreement or commitment
precluding such party or its Affiliates from making it available to the other
party. "Senetek Know-How" means Know-How owned or controlled by Senetek or its
Affiliates and "Vivier Know-How" means Know-How owned or controlled by Vivier or
its Affiliates.

      1.13  "Net Royalties" means the gross royalties received by Senetek or its
Affiliates from sales of Products by its licensees or sub-licensees, less only
(to the extent consistent with reasonable industry practices and shown on
customer invoices as separate items) amounts actually allowed or credited by
Senetek or its Affiliates for returns of such Products, calculated in accordance
with United States generally accepted accounting principles applied consistently
from period to period, provided that Net Royalties shall not include any pass
through costs invoiced to licensees or sub-licensees as separate items for
freight or shipping insurance.

      1.14  "Net Sales" means the gross revenues of a Party or its Affiliates
from sales of Products to non-Affiliates, less only (to the extent consistent
with reasonable industry practices and shown on customer invoices as separate
items) (i) the amount of discounts and allowances granted by the Party or its
Affiliates and taken by such non-Affiliate customers with respect, thereto and
(ii) amounts actually allowed or credited by the Party or its Affiliates for
returns of such Products, calculated in accordance with United States generally
accepted accounting principles applied consistently from period to period,
provided that Net Sales shall not include Net Royalties or any pass through
costs invoiced to customers as separate items for freight or shipping insurance.

      1.15  "Patents" means the patents for Kinetin set forth on Schedule
1.15A (the "Senetek Patents") and the patent applications for Vivier C set forth
on Schedule 1.15B (the "Vivier Patents").

      1.16  "Person" shall be broadly construed to include any Government
Entity, legal entity, or natural person.

      1.17  "Products" means, collectively (a) those existing formulations
containing Vivier C set forth in Schedule 1.17 and any improvements of such
products and new formulations containing Vivier C not in combination with
Kinetin developed by Vivier after the Agreement Date (the "Vivier C Products"),
and (b) those formulations containing Vivier C in combination with Kinetin
mutually agreed upon by the Parties, including formulations that combine other
active ingredients, but excluding (i) any product subject to regulation as a
prescription drug and (ii) any product with a concentration of Kinetin of [***]
or more (the "Kinetin C Products").

      1.18  "Territory" means Canada and the United States of America.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        3

<PAGE>

Confidential Treatment Requested
--------------------------------

      1.19  "Term" means the period starting on the Agreement Date and ending
(if not earlier terminated pursuant to the other terms of this Agreement) at the
end of the fifth Contract Year, unless extended by agreement of the parties.

      1.20  "Trial Size" means a Unit that is a sampling vehicle with a fill
weight that is less than 25% of the fill weight of regular business Product and
that is given to customers or end-use consumers free of charge with the
objective of generating trial and awareness of Products.

      1.21  "Unit" means an individual packaged unit of Product.

      1.22  "Valid Claim" means any claim in an unexpired patent or patent
application that has not been disclaimed or held invalid or unenforceable by a
Governmental Entity of competent jurisdiction in a Final Adjudication.

2.    CROSS-LICENSES; PRODUCT MANUFACTURE AND SUPPLY

      2.1   Grants of Licenses.

            2.1.1 Senetek hereby grants to Vivier during the Term a license
under the Senetek Intellectual Property to manufacture, have manufactured,
market and sell Kinetin C Products in the Authorized Channel in the Territory,
and to use the Senetek Intellectual Property, Improvements and Documentation to
facilitate such manufacture, marketing and sale, in each case subject to the
terms of this Agreement.

            2.1.2 Vivier hereby grants to Senetek during the Term a license
under the Vivier Intellectual Property to market and sell and license third
parties to market and sell the Products in all channels of distribution
throughout the world, and to use the Vivier Intellectual Property, Improvements
and Documentation to facilitate such marketing, sale and licensing, in each case
subject to the terms of this Agreement, except that Senetek shall not market or
sell or license third parties to market or sell (a) any Products in the
Authorized Channel in Canada, (b) any Vivier C Products in the Authorized
Channel in the United States, or (c) any Products in the drug store class of
trade in Japan, without the express prior approval of Vivier in writing.

      2.2   Exclusivity. Senetek agrees that during the Term, Senetek and its
Affiliates will not (i) manufacture, have manufactured, market or sell Products
in the Authorized Channel in Canada or in the drug store class of trade in Japan
or Vivier C Products in the Authorized Channel in the United States, (ii)
manufacture, have manufactured, market or sell Products otherwise than as
excluded by clause (i) except in accordance with this Agreement, or (iii)
license any other Person so to do (the "Exclusivity Right"). Nothing in this
Agreement shall be construed to limit Senetek's right to use or license the
Senetek Intellectual Property, Improvements or Documentation otherwise than as
provided in Section 2.1.1.

      2.3   Royalty Payable by Vivier. A royalty shall be due to Senetek with
respect to all sales of Kinetin C Products by Vivier or its Affiliates
calculated at the rate of [***] of Vivier's and its Affiliates' Net Sales of all
Kinetin C Products except for Trial Sizes provided free of charge, provided that
such royalty shall not in any case be less than [***] per
Unit other than

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        4

<PAGE>

Confidential Treatment Requested
--------------------------------

Trial Sizes. All royalties shall be paid with respect to each Calendar Quarter
within 30 days after the end of such Calendar Quarter. Payments shall be made by
wire transfer to the bank account designated by Senetek from time to time in
U.S. Dollars, and any late payments shall be subject to a handling charge of
one-and-one-half (1-1/2) percent per month until paid in full. All royalty
payments shall be accompanied by a reasonably detailed accounting setting forth
the basis upon which such payment was calculated. Royalties due shall not be
subject to any offset for any claim Vivier may have against Senetek unless and
until such claim is approved by Senetek in writing or determined to be valid in
a Final Adjudication pursuant to the dispute resolution procedures set forth in
this Agreement.

      2.4   Product Manufacture; Packaging and Promotion of Vivier Product.

      2.4.1 Vivier shall manufacture all Products at its present contract
manufacturers, Therapex or Delta, unless specifically agreed otherwise by both
Parties in writing. All Products shall be manufactured in full compliance with
all applicable good manufacturing practices requirements applicable within the
Territory. Unless otherwise approved by Senetek, Vivier will purchase its
supplies of Kinetin solely from Senetek or its authorized vendor at Senetek's
fully-loaded cost as in effect from time to time. In the event that Senetek
shall approve Vivier otherwise sourcing Kinetin, the purity of Kinetin utilized
by Vivier in Products shall be no less than [***] with proof of biological
activity or other efficacy of the Products established by Vivier or its supplier
using such means and at such frequency as Senetek may reasonably require.
Senetek shall have the right to conduct reasonable audits of Vivier's contract
manufacturing sites and its and its contract manufacturers' quality
assurance/quality control procedures for raw materials, componentry, packaging
and finished product.

      2.4.2 Senetek shall provide Vivier with all technical and other
information in its possession regarding formulating with Kinetin to enable
Vivier to perform its obligations under and obtain the benefits of this
Agreement. Vivier agrees that in marketing and selling Products it shall not
make any comparative claims with respect to Kinetin-containing products of other
Senetek licensees. Vivier shall submit to Senetek all packaging, labeling and
promotional materials intended to be used for Kinetin C Products to be marketed
and sold by Vivier, solely for Senetek's approval of Product claims and Senetek
trademark usage, such approval not to be unreasonably withheld or delayed (it
being agreed that such review shall not affect any of Senetek's rights of
indemnification hereunder). All Kinetin C Product packaging for Products to be
marketed and sold by Vivier shall, to the extent that space can reasonably
accommodate the same, include the following or a similar statement presented in
a manner consistent with industry practice: "Manufactured and sold under license
from Senetek PLC " with the patent number applicable in the country of sale
indicated.

      2.5   Purchases by Senetek. In the case of Product marketed and sold by
Senetek or its Affiliates or its or their licensees or sub-licensees pursuant to
Section 2.1.2, Senetek agrees that, subject to Section 2.5.4, all such Product
shall be purchased from Vivier in accordance with this Section 2.5 and Vivier
agrees to use Best Efforts to fulfill such orders in accordance with the terms
hereof.

      2.5.1 Senetek shall place all orders for Product, whether for its own
marketing and sale or for marketing and sale by its licensees, directly with
Vivier by facsimile copy of its Purchase

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        5

<PAGE>

Order confirmed by mail. Vivier shall confirm acceptance of each Purchase Order
by facsimile copy confirmed by mail, within one week following receipt of the
facsimile copy of Senetek's Purchase Order. Senetek shall provide to Vivier no
less frequently than every six months a rolling twelve (12) month forecast of
Senetek's and its licensees' requirements for Products. If Senetek or its
licensee order packaged product, such packaging and labeling shall either be
supplied by their supplier or shall be sourced by Vivier in accordance with
specifications developed by Senetek.

      2.5.2 Vivier shall use its Best Efforts to ship Products to Senetek or
its licensee within ninety (90) days after receipt of Senetek's Purchase Order,
provided that for any Product for which packaging art or copy is not approved by
Senetek on the date of the order, Vivier shall use its best efforts to ship such
Product within the later of one hundred twenty (120) days after receipt of
Senetek's Purchase Order or sixty (60) days after final approval of such art or
copy. Vivier agrees that in scheduling purchases and production it shall require
its contract manufacturers to accord Senetek's and its licensees' orders the
same priority it accords to Vivier's orders. All deliveries shall be FOB such
contract manufacturers' shipping dock, and risk of any loss or damage of or to
the Products delivered shall pass to Senetek or its licensees when Products are
locked on board the contracted carrier, provided that Senetek or its licensee
shall have thirty (30) days after delivery to reject any Product if manifestly
damaged or defective at point of shipment. At Senetek's or its licensee's
request and expense, Vivier shall arrange for shipping to Senetek's or its
licensees' designated destination. Vivier shall be solely responsible for
compliance with all export and like regulations in the case of shipments outside
of Canada, and Senetek or its licensees shall be solely responsible for all
customs, import and like regulations related to the import, storage, shipment
and sale of Products.

      2.5.3 Vivier shall invoice Senetek the full Base Price (as defined in
Section 2.5.5) for Product shipped, whether to Senetek or its licensees, and
payment shall be due thirty (30) days after invoice. Payments shall be made by
wire transfer to the bank account designated by Vivier in United States Dollars,
and late payments shall be subject to a handling fee of one-and-one-half (1-1/2)
percent per month until payment in full, except in the case of any disputed
amounts.

      2.5.4 Notwithstanding the foregoing, in the event that either Party
shall identify a potential manufacturer of Products at materially lower prices
than those offered by the contract manufacturers provided for in Section 2.4.1,
the other Party shall consider utilizing such manufacturer (a "Third Party
Manufacturer"), subject to such Third Party Manufacturer's compliance with all
requirements of Section 2.4.1 and its conformance to the Parties' respective
production, quality assurance and quality control requirements, provided that
either Party may, in its sole discretion, decline to make any change in the
manufacturing arrangements set forth in Section 2.4.1 or may impose such
limitations on such manufacture as it may determine, in each case in its sole
discretion, or require termination of such Third Party Manufacturer in the event
that it ceases to comply with Section 2.4.1, the Parties' respective production,
quality assurance and quality control requirements, or a Party's limitations
imposed hereunder.

      2.5.5 The base price for Products purchased by Senetek or its licensees
from Vivier shall be the sum of (i) Vivier's fully loaded cost of goods for bulk
Product (the "Bulk Cost") plus (ii) for Product in packaged form, Vivier's fully
loaded cost of goods and charges for the primary packaging, any package inserts,
any secondary packaging and any shipping cartons (the

                                        6

<PAGE>

Confidential Treatment Requested
--------------------------------

"Packaging Cost") plus any freight-in (collectively, the "Base Price"). Promptly
upon establishment by Vivier of the Bulk Cost of each Product to be manufactured
and sold by Vivier, Vivier shall supply to Senetek a detailed statement of such
Bulk Cost.

     2.5.6 Senetek shall pay to Vivier royalties as follows: (i) on Products
sold by Senetek or its Affiliates in finished, packaged form directly to
non-Affiliate distributors, retailers or other customers, a royalty calculated
at the rate of [***] of Senetek's and its Affiliates' Net Sales of all Products
except for Trial Sizes provided free of charge, provided that such royalty shall
not in any case be less than [***] per Unit other than Trial Sizes, (ii) on
Products sold by licensees or sub-licensees of Senetek or its Affiliates upon
which a royalty is payable to Senetek or its Affiliates (whether a percentage of
net sales or an amount per unit sold by such licensees or sub-licensees), a
royalty calculated at the rate of [***] of Senetek's or its Affiliates Net
Royalties, and (iii) on Products supplied in bulk by Senetek or its Affiliates
to licensees or sub-licensees for packaging, marketing and sale by them for
which a royalty is not payable to Senetek or its Affiliates, a royalty
calculated at the rate of [***] of the Base Price of such bulk Product, or if
such Product is manufactured by a Third Party Manufacturer selected by Senetek
as provided in Section 2.5.4, a royalty calculated at the rate of [***] of
Senetek's or its Affiliates' purchase price of such bulk Product. All royalties
shall be paid with respect to each Calendar Quarter within 30 days after the end
of such Calendar Quarter. Payments shall be made by wire transfer to the bank
account designated by Vivier from time to time in U.S. Dollars, and any late
payments shall be subject to a handling charge of one-and-one-half (1-1/2)
percent per month until paid in full. All Royalty payments shall be accompanied
by a reasonably detailed accounting setting forth the basis upon which such
payment was calculated. Royalties due shall not be subject to any offset for any
claim Senetek may have against Vivier unless and until such claim is approved by
Vivier in writing or determined to be valid in a Final Adjudication pursuant to
the dispute resolution procedures set forth in this Agreement.

     2.5.7 In the event that either Party shall propose to the other a
Products-related transaction different than those for which royalties are
provided for in Section 2.3 or 2.5.6, the Parties agree to negotiate in good
faith with respect to the feasibility of such transaction and, if the Parties
agree upon its feasibility, the royalty or other consideration to be payable and
the other terms and conditions to apply to such transaction.

     2.6   Books and Records. Each Party shall maintain books and records
reflecting all amounts included in its calculation of royalties set forth in
each royalty report and all other amounts due to the other pursuant to Section
2.3, 2.5.6 or 2.5.7. Senetek shall maintain books and records reflecting all
amounts included in its calculation of its fully loaded cost of Kinetin supplied
to Vivier and the purchase price of any bulk Product purchased from any Third
Party Manufacturer. Vivier shall maintain books and records reflecting its
calculation of the Base Prices of Products supplied to Senetek, its Affiliates
or their licensees or sub-licensees pursuant to Section 2.5. All such books and
records shall be prepared in accordance with generally accepted accounting
standards and each Party shall maintain source documentation of the amounts
therein reflected and shall provide the other Party with reasonable access, upon
at least ten (10) days prior notice and at times not unreasonably disruptive of
its operations, to conduct audits thereof. No more than one such audit shall be
conducted during any twelve (12) month

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        7

<PAGE>

Confidential Treatment Requested
--------------------------------

period unless an audit documents an error in amounts reported or charged of more
than ten (10) percent during the period covered by the audit, in which event
audits may be conducted semi-annually thereafter until such audits fail to
document such an error. The Party determined to have been in error in amounts
reported or charged shall pay a handling charge of one-and-one-half (1-1/2)
percent per month from the date of such erroneous report or charge to the date
on which the same is corrected by payment. The costs of any such audit shall be
borne by the Party conducting it unless such audit documents an error of more
than ten (10) percent during the period covered by the audit, in which case such
costs shall be reimbursed by other Party.

      2.7 Clinical Trials Funding. Vivier acknowledges that Senetek has
heretofore performed [***] clinical testing of Kinetin, including without
limitation the testing reflected in the Senetek Documentation set forth in
Schedule 1.8A, at the University of California--Irvine ("UCI") in accordance
with protocols acceptable for prescription drug product testing. Vivier agrees,
promptly after execution of this Agreement, to design and fund equivalent tests
of Vivier C (except that such clinical testing may be limited to 90 days'
duration) at UCI or such other institution of comparable standing in the
pharmaceuticals industry as the parties may agree (the "Vivier C Testing"),
except to the extent Vivier provides to Senetek adequate documentation of
equivalent tests already performed using comparable protocols at an institution
of standing comparable to UCI. In addition, promptly after execution of this
Agreement, the parties shall develop and conduct tests of Kinetin C (the
"Kinetin C Testing"), using such protocols and methodologies as the parties may
agree, with the costs of such testing to be shared equally, provided that
neither party shall be required to pay more than [***] of such costs. Vivier
further agrees that Senetek may supplement the Vivier C Testing or the Kinetin C
Testing with such additional tests and trials of Kinetin, such as infrared
photography and tests of moisture barrier enhancement, as Senetek may wish in
order to update the tests referred to in Schedule 1.8A (the "Supplemental
Kinetin Testing"), with all costs to be borne by Senetek. Vivier shall be the
sole owner of the results of the Vivier C Testing, Senetek shall be the sole
owner of the results of the Supplemental Kinetin Testing, and the Parties shall
jointly own the results of the Kinetin C Testing; provided that the owner of
such testing shall permit the other Party to use such results in exploiting its
rights with respect to Products hereunder, and provided further that no Party
shall use any such results, whether owned by it or by the other Party or jointly
owned, to make any claims or statements, comparative or otherwise, with respect
to any products of the other Party or its Affiliates or licensees.

No Other Rights. It is expressly understood that this Agreement grants no
rights to Vivier or Senetek with respect to the Intellectual Property or
Confidential Information of the other Party except those express rights set
forth in this Article 2. Without limiting the foregoing, it is understood and
agreed that Vivier has no right pursuant to this Agreement to, and shall not,
(i) manufacture, have manufactured, or sell or knowingly permit its customers to
sell any Products other than into the Authorized Channel within the Territory to
the extent it is legally permissible to prohibit or restrict such activity, or
(ii) manufacture, have manufactured, market or sell products containing Kinetin
that are not Products, and Senetek has no right pursuant to this Agreement to,
and shall not, market or sell or license third parties to market or sell
Products other than in accordance with Section 2.1.2 and 2.5. Upon any
termination of this Agreement, Vivier shall not have any right of any kind with
respect to the Kinetin C Products or the Senetek Intellectual Property or
Confidential Information, and Senetek shall not have any right of any kind with
respect to the Products or the Vivier Intellectual Property or Confidential
Information,

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        8

<PAGE>

Confidential Treatment Requested
--------------------------------

other than the right to complete the sale within six months of such termination
of Products then lawfully in its possession (in the case of Senetek and its
licensees) or Kinetin C Products then in its possession or manufactured into
bulk (in the case of Vivier), subject to full payment of the Base Price or
Royalty due therefore (as the case may be). Nothing in the foregoing sentence
shall diminish either party's rights in its own trademarks or other Intellectual
Property, provided that following termination of this Agreement and any sell-off
period provided for above, neither party shall use its own trademarks or
packaging or promotional materials in a manner that may misleadingly suggest
that such party continues to practice its rights under this Agreement. It is
expressly understood that all Product formulations developed by either party
pursuant to this Agreement shall be the sole property of the party developing
the same, and such party shall be entitled to file, prosecute, own and maintain
worldwide patent rights on the same, provided, however, that Vivier shall not
conduct any [***] testing of any such formulation containing Kinetin except
under Senetek's control and, provided, further, that in no event may any patents
or patent applications so filed by either party contain any claims that are
within the Valid Claims of the other party's Patents or that, in the absence of
a patent license from the patenting party, would restrict the other party or any
assignee or licensee of the other party from making, using, or selling any
product practicing its Patents.

3.    REPRESENTATIONS, WARRANTIES AND CERTAIN COVENANTS OF THE PARTIES

      3.1   Representations, Warranties and Covenants of Vivier. Vivier
represents, warrants and covenants as follows:

            3.1.1 Qualifications and Authorization. Vivier is a corporation duly
formed, validly existing and in good standing under the laws of Quebec, Canada,
with full corporate power and authority to conduct its business as it is now
conducted and to enter into and perform this Agreement. Vivier is duly licensed
or qualified to do business and is in good standing in each jurisdiction in
which its operations or ownership of assets requires such licensing or
qualification.

            3.1.2 No Conflict or Violation. Neither the execution, delivery or
performance of this Agreement, nor compliance by Vivier with any of the
provisions hereof, will (i) violate or conflict with any provision of the
Certificate or Articles of Incorporation or Bylaws of Vivier, (ii) violate,
conflict with, or result in a breach of any provision of, or constitute a
default (or an event which, with notice or lapse of time or both, would
constitute a default) under, or result in the creation of any encumbrance upon
any of Vivier's assets under, any of the terms, conditions or provisions of any
material contract, indebtedness, note, bond, indenture, security or pledge
agreement, commitment, license, lease, franchise, permit, agreement, or other
instrument or obligation to which Vivier is a party, or (iii) violate any
statute, rule, regulation, ordinance, code, order, judgment, ruling, writ,
injunction, decree or award applicable to Vivier, except, in the case of each of
clauses (i), (ii) and (iii) above, for such violations, conflicts, breaches,
defaults or creations of encumbrances which, in the aggregate, would not have a
material adverse affect on the business of Vivier taken as a whole or on its
ability to fully perform this Agreement.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        9

<PAGE>

Confidential Treatment Requested
--------------------------------

            3.1.3 Compliance with Laws. Vivier shall and shall assure that its
contract manufacturers shall comply with all laws, regulations, ordinances,
orders, injunctions, decrees and requirements applicable to the manufacturing,
packaging, storage, shipment and export of all Products, and to its marketing
and sale of Kinetin C Products. Without limiting the foregoing, Vivier shall
assure that its contract manufacturer produces and packages (if applicable) the
Products in full compliance with all applicable good manufacturing practices
requirements for the Territory, shall conduct appropriate stability testing of
the Products, shall maintain and implement appropriate quality control and
quality assurance procedures for all raw materials and componentry, whether
produced internally or supplied by vendors, and all bulks, work in process and
finished goods, shall package, label and advertise Kinetin C Products marketed
and sold by it in accordance with all applicable legal requirements and in a
manner not infringing or violating any intellectual property or trade rights of
third Persons, and shall obtain and maintain all Product marketing approvals,
registrations or other permits necessary for the lawful manufacture, packaging,
storage, shipment and export, and for its marketing and sale of the Kinetin C
Products in the Authorized Channel within the Territory.

            3.1.4 Product Launch. Vivier will begin marketing the initial
Kinetin C Products in Canada not later than [***] and the initial Kinetin C
Products in the United States of America not later than [***].

            3.1.5 Vivier C Products. Schedule 1.17 contains a true and complete
list of all formulations of products containing Vivier C that have been
developed by or for Vivier as of the Agreement Date. During the Term, Vivier
shall promptly notify Senetek of any and all improvements to the formulations
set forth in Schedule 1.17 and any new formulations developed by or for Vivier
containing Vivier C.

            3.1.6 Acknowledgement of Senetek Patents' Validity, Enforceability
and Ownership. In consideration of the benefits of Sections 2.1.1 and 2.2,
Vivier, for itself and its Affiliates, successors and permitted assigns and
sub-licensees, irrevocably acknowledges, admits and concedes that (i) all
rights, title and interest in the Senetek Patents are owned by Senetek and its
Affiliates, (ii) all claims of the Senetek Patents as well as all claims that
are narrower in scope than the claims of the Senetek Patents are valid and
enforceable, and (iii) all claims of any patent that may issue from any
application whose subject matter in whole or in part is entitled to the benefit
of the filing date(s) of the Senetek Patents (including, without limitation,
continuations, continuations-in-part, divisional patents, reexaminations,
renewals, extensions, reissues, and foreign counterparts) that are equal to or
narrower in scope than the claims of the Senetek Patents are valid and
enforceable. Vivier, for itself and its Affiliates, successors and permitted
assigns and sub-licensees, does also forever relinquish and waive all rights to
dispute said ownership, validity and enforceability in any proceeding of any
nature, covenants that it and they will not assert, either affirmatively or
defensively, in any proceeding of any nature, any matter inconsistent with said
ownership, validity and enforceability, agrees and acknowledges that the
foregoing shall act as a complete defense and bar to any proceeding of any
nature challenging such ownership, validity and enforceability or any of them,
and consents to the entry of temporary and permanent injunctions to bar any
breach or threatened breach of any of the foregoing, without the filing on
behalf of Senetek of any bond or other security.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                       10

<PAGE>

            3.1.7 No Unsolicited Bids. Vivier, for itself and its Affiliates,
successors and permitted assigns and sub-licensees, irrevocably agrees that from
the Agreement Date through the fifth anniversary of the end of the Term it and
they will not, individually or as a member of any "group" (as such term is
defined under the United States Securities Exchange Act) (i) purchase, own or
acquire rights in securities of Senetek or American Depositary shares
representing, or options, warrants or other rights to purchase, securities of
Senetek, representing in the aggregate 1% or more of the outstanding equity
securities of Senetek, or (ii) make any public or confidential offer or proposal
to Senetek or its management or Board of Directors or any member thereof with a
view to entering into any acquisition of or combination involving Senetek or any
of its material assets, or (iii) participate in any proxy contest or other
process intended to cause the adoption of any shareholder resolution which has
not been recommended for adoption by the Board of Directors of Senetek.

      3.2   Representations and Warranties and Covenants of Senetek.  Senetek
represents, warrants and covenants as follows:

            3.2.1 Qualifications and Authorization. Senetek is a corporation
duly formed, validly existing and in good standing under the laws of the United
Kingdom with full corporate power and authority to conduct its business as it is
now conducted and to enter into and perform this Agreement. Senetek is duly
licensed or qualified to do business and is in good standing in California and
each other jurisdiction in which its operations or ownership of assets in
connection with this Agreement requires such licensing or qualification.

            3.2.2 No Conflict or Violation. Neither the execution, delivery or
performance of this Agreement, nor compliance by Senetek with any of the
provisions hereof, will (i) violate or conflict with any provision of the
Certificate of Incorporation or Bylaws of Senetek, (ii) violate, conflict with,
or result in a breach of any provision of, or constitute a default (or an event
which, with notice or lapse of time or both, would constitute a default) under,
or result in a creation of any encumbrance upon any of Senetek's assets under,
any of the terms, conditions or provisions of any material contract,
indebtedness, note, bond, indenture, security or pledge agreement, commitment,
license, lease, franchise, permit, agreement, or other instrument or obligation
to which Senetek is a party, or (iii) violate any statute, rule, regulation,
ordinance, code, order, judgment ruling, writ, injunction, decree or award
applicable to Senetek, except, in the case of each of clauses (i), (ii) and
(iii) above, for such violations, conflicts, breaches, defaults or creations of
encumbrances which, in the aggregate, would not have material adverse effect on
the business of Senetek taken as a whole or on its ability to perform this
Agreement.

            3.2.3 Compliance with Laws. Senetek shall, and shall cause its
licensees which purchase Products to, comply with all laws, regulations,
ordinances, orders, injunctions, decrees and requirements applicable to the
importation, marketing and sale of the Products, including by obtaining and
maintaining all Product marketing approvals, registrations or other permits
necessary for the lawful importation, exportation (if applicable), storage,
shipment, marketing and sale of the Products pursuant to Section 2.1.2. Senetek
covenants that packaging and labeling produced by Vivier in accordance with any
specifications supplied by Senetek to Vivier or supplied by Senetek for use in
packaging Products will comply with all laws and regulations applicable in the
countries in which such Products are to be sold and will not infringe or violate
the intellectual property or trade rights of any third Person.

                                       11

<PAGE>

            3.2.4 Acknowledgement of Vivier Patents' Validity, Enforceability
and Ownership. In consideration of the benefits of Section 2.5, Senetek, for
itself and its Affiliates, successors and permitted assigns and sub-licensees,
irrevocably acknowledges, admits and concedes that (i) all rights, title and
interest in the Vivier Patents are owned by Vivier and its Affiliates, (ii) all
claims of the Vivier Patents as well as all claims that are narrower in scope
than the claims of the Vivier Patents are valid and enforceable, and (iii) all
claims of any patent that may issue from any application whose subject matter in
whole or in part is entitled to the benefit of the filing date(s) of the Vivier
Patents (including, without limitation, continuations, continuations-in-part,
divisional patents, reexaminations, renewals, extensions, reissues, and foreign
counterparts) that are equal to or narrower in scope than the claims of the
Vivier Patents are valid and enforceable. Senetek, for itself and its
Affiliates, successors and permitted assigns and sub-licensees, does also
forever relinquish and waive all rights to dispute said ownership, validity and
enforceability in any proceeding of any nature, covenants that it and they will
not assert, either affirmatively or defensively, in any proceeding of any
nature, any matter inconsistent with said ownership, validity and
enforceability, agrees and acknowledges that the foregoing shall act as a
complete defense and bar to any proceeding of any nature challenging such
ownership, validity and enforceability or any of them, and consents to the entry
of temporary and permanent injunctions to bar any breach or threatened breach of
any of the foregoing, without the filing on behalf of Vivier of any bond or
other security.

            3.2.5 Kinetin. The Kinetin supplied by Senetek for use in the
manufacture of the Products shall comply with the standards applicable to Vivier
as set forth in Section 2.4.

      3.3   Representations and Warranties and Covenants of Each Party.  Each
party represents, warrants and covenants with the other party as follows:

            3.3.1 Patents. Each party owns its Patents and either owns or holds
licenses for the use of its other Intellectual Property and Documentation, and
has the full and unrestricted right to license them to the other party and, in
the case of Section 2.1.2, to third parties to which licenses may be granted by
Senetek. Neither party has any knowledge of the existence of any patents or
patent applications, trademarks or trademark applications, or copyrights owned
by any Person except the other party or its Affiliates that would prevent it
from making, having made, or selling Products under its Patents or other
Intellectual Property pursuant to Section 2.1. As of the date of this Agreement,
neither party has entered into any subsisting material license agreement with
respect to its Patents except as disclosed on Schedule 3.3.1A or 3.3.1B,
respectively, and except as disclosed on such respective Schedules, neither
party is involved in any material dispute with respect to the agreements
identified on such schedule or with respect to any other Person challenging the
ownership, validity or enforceability of its Patents.

            3.3.2 Product Claim Substantiation; Testing Data. Each party has
made available to the other all formal research reports prepared by or for it
with respect to the utilization of its Patents in skin care or cosmetic
products, including in the case of Senetek all UCI test data and copies of
"results" photographs taken by Canfield Scientific, and each party will continue
to make available to the other all future Product claim substantiation and
safety, efficacy and other testing data and all marketing materials related to
the Products, as may be

                                       12

<PAGE>

reasonably necessary to permit the other party to promote the Products pursuant
to Section 2.2 and 2.5, provided that neither party shall be required to
disclose any such information to the extent that doing so would violate
agreements with other Persons if it has used Best Efforts to obtain a waiver or
amendment of such provisions to permit such disclosure. All such data shall be
deemed Confidential Information of the disclosing party for all purposes of this
Agreement.

4.    CONFIDENTIAL INFORMATION AND ANNOUNCEMENTS

      4.1   Senetek Confidential Information. Vivier shall not (a) use Senetek
Confidential Information except to perform its obligations or exercise its
rights under this Agreement, or (b) disclose Senetek Confidential Information to
any Person (except to its employees and agents who reasonably require same for
the purpose hereof and who are bound to Vivier by the same obligations as to
confidentiality) otherwise than as provided in this Agreement without the
express written permission of Senetek, unless such disclosure is required by
order of a court of competent jurisdiction (in which event Vivier shall give
notice to Senetek and use Best Efforts to afford it the opportunity to contest
such requirement).

      4.2   Vivier Confidential Information. Senetek shall not (a) use Vivier
Confidential Information except to perform its obligations or exercise its
rights under this Agreement, or (b) disclose Vivier Confidential Information to
any Person (except to its employees and agents who reasonably require same for
the purpose hereof and who are bound to Senetek by the same obligations as to
confidentiality) otherwise than as provided in this Agreement without the
express written permission of Vivier, unless such disclosure is required by
order of a court of competent jurisdiction (in which event Senetek shall give
notice to Vivier and use Best Efforts to afford it the opportunity to contest
such requirement).

      4.3   No License. The furnishing of Confidential Information by one party
to the other shall not constitute any grant, option or license to the other
under any Patent or Intellectual Property of the furnishing party.

      4.4   Announcements. The parties will issue an agreed upon press release
upon the execution of this Agreement in the form set forth in Schedule 4.4.
Except for such release and except as may otherwise be required by law or the
listing rules of any exchange on which either party's securities may be listed
or quoted, for which the releasing party shall provide prior notice to the other
party and the opportunity to comment on any required disclosure, neither party
will disclose the terms of this Agreement to any other Person; provided,
however, that each party may make such disclosure of the terms of this Agreement
to its employees and agents as is necessary to permit such party to perform its
obligations under this Agreement; provided further that any such employee or
agent agrees to maintain the confidentiality of this Agreement; and provided
further that either party may make such disclosures of the terms of this
Agreement as are necessary to enter into license and other agreements that do
not conflict with the terms of this Agreement. Vivier acknowledges that this
Agreement may be deemed to be a "material contract" as that term is defined by
Item 601(b)(10) of Regulation S-K, and that Senetek may therefore be required to
file such document as an exhibit to reports or registration statements filed
under the United States Securities Act or Securities Exchange Act, provided that
Senetek

                                       13

<PAGE>

Confidential Treatment Requested
--------------------------------

shall redact commercial terms and file for confidential treatment to the extent
permitted by applicable rules of the United States Securities and Exchange
Commission.

      4.5   Release from Restrictions. The restrictions set forth in Sections
4.1 and 4.2 shall not apply to Vivier or Senetek Confidential Information
disclosed to the other party (i) that a party rightfully possessed before it
received the information from the other as evidenced by written documentation;
(ii) that subsequently becomes publicly available through no fault of that
party; (iii) that is subsequently furnished rightfully to that party by a third
party that is not an Affiliate and which is not known to be under restrictions
on such disclosure; or (iv) that is independently developed by an employee,
agent or contractor of such party.

      4.6   Survival. The provisions of this Article 4 shall survive termination
of this Agreement and continue thereafter for a period of five (5) years;
provided, however, that each party's obligations with respect to any
Confidential Information of the other party that is Documentation or Know-How
shall survive until the expiration of the last to expire of the Valid Claims of
the other party's Patents.

5.    DISPUTE RESOLUTION

      5.1   Disputes.  All disputes between the parties to this Agreement shall
be subject to and resolved in accordance with the terms of Schedule 5.2, which
shall be binding on the parties.

6.    INDEMNIFICATION, INSURANCE AND LIMITS ON LIABILITY

      6.1   Indemnification by Vivier. Vivier shall defend, indemnify, and hold
harmless Senetek, its officers, agents, employees and Affiliates from any loss,
claim, action, damage, expense or liability (including defense costs and
attorneys' fees) (collectively, "Claims") arising out of or related to a breach
or alleged breach of any representation, warranty or covenant made by Vivier
herein, or the manufacture, handling, possession of any Product to the point of
shipment to Senetek or its licensees, or the marketing, sale or other use of
Products marketed or sold by Vivier, except insofar as any such Claim is related
to or arises from Senetek's negligence or breach of any representation, warranty
or covenant made by Senetek in this Agreement.

      6.2   Indemnification by Senetek. Senetek shall defend, indemnify, and
hold harmless Vivier, its officers, agents, employees and Affiliates from any
Claims arising out of or related to a breach or alleged breach of any
representation, warranty, or covenant made by Senetek herein or the marketing,
sale or other use of Products marketed or sold by Senetek or its licensees,
except insofar as any such Claim is related to or arises from Vivier's
negligence or breach of any representation, warranty or covenant made by Vivier
in this Agreement.

     6.3 Insurance. Vivier shall maintain at its expense commercial general
liability insurance (including products liability coverage) with an insurance
company or companies rated at least Best AA in a principal amount of not less
than the coverage generally maintained by Vivier in the ordinary course and in
any case aggregating no less than [***] per occurrence, with no annual aggregate
limit. Such policy shall name Senetek as an additional insured. Within thirty
(30) calendar days after the date of this Agreement, Vivier shall furnish to
Senetek a certificate evidencing such insurance. Senetek may elect to suspend
the license granted hereunder until such insurance is in place and the
certificate

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                       14

<PAGE>

of coverage is provided, and may thereafter suspend the license granted
hereunder if it reasonably believes such insurance is not in place until Vivier
provides Senetek reasonable assurance that such coverage is in place without any
gap in coverage during the Term and will be maintained as required by this
Agreement.

      6.4   No Consequential Damages. Except for (i) Claims that include
consequential damages paid to Persons that are not Affiliates of an indemnified
Party, (ii) Claims by Vivier based upon failure of Senetek to timely supply
Kinetin for Vivier's use in producing Kinetin C Products, and (iii) Claims by
Senetek based on failure of Vivier to timely supply Products in accordance with
Section 2.5, neither party shall be liable to the other for consequential
damages, lost profits, injury to reputation or similar claims; provided,
however, that nothing in this sentence shall be construed to in any way limit a
Party's obligation to pay the royalties and other amounts due to the other Party
under this Agreement. UNDER NO CIRCUMSTANCES SHALL EITHER PARTY OR ITS
AFFILIATES HAVE ANY LIABILITY TO THE OTHER PARTY ARISING FROM THIS AGREEMENT IN
EXCESS OF THE HIGHEST AGGREGATE AMOUNT RECEIVED FROM THE OTHER PARTY OVER THE
COURSE OF ANY THREE CONSECUTIVE CONTRACT YEARS (OR IF THREE CONSECUTIVE CONTRACT
YEARS SHALL NOT HAVE ELAPSED, IN EXCESS OF 300% OF THE AMOUNT RECEIVED FROM THE
OTHER PARTY OVER THE COURSE OF THE MOST RECENT CONTRACT YEAR). Each party
acknowledges and agrees that, but for the limitations of liability set forth in
this Section, the other party would not have entered into this Agreement upon
the terms set forth herein and that such limitations are a material part of this
Agreement.

      6.5   Recalls. In the event any Product(s) must be recalled from
distribution by reason of failure to meet any requirements of law or otherwise,
Vivier (in the case of Kinetin C Products sold by it) or Senetek (in the case of
Products sold by it or its licensees) shall have the sole responsibility to
conduct such recall, with the reasonable assistance of the other party to the
extent necessary and requested. Responsibility for payment of the costs of such
recall shall be borne by the party required to indemnify therefore pursuant to
this Article 6.

7.    INFRINGEMENT

      7.1   Notification of Infringement. During the Term, each party shall
promptly advise the other in writing of any infringement, imitation or act by
third parties inconsistent with the ownership of and rights to the Intellectual
Property as represented in this Agreement or any act of unfair competition by
third parties (any of the foregoing shall be referred to as an "infringement")
relating to any of the Intellectual Property or the Know-How wherever and
whenever such infringement or act shall come to the attention of such party. If
such infringement occurs within the Territory, the party owning or claiming the
Intellectual Property infringed (the "Proprietor") shall promptly take such
commercially reasonable action as is required to restrain such infringement or
otherwise enforce its rights in the Intellectual Property and the other party
shall cooperate fully with the Proprietor in such action and, if so requested,
shall join with the Proprietor as a party to any appropriate legal proceedings
for such purpose. The Proprietor shall bear all expenses in connection with the
foregoing. In the event that within a reasonable time after the Proprietor
becomes aware of such infringement within the Territory, the Proprietor fails to
take appropriate and diligent action with respect to such infringement, the

                                       15

<PAGE>

other party shall have the right, to the extent permitted by law, to institute
an action for infringement at its own expense, and in its own name, or in the
name of any of its Affiliates and the right to enforce and collect any judgment
thereon.

      7.2   Recovery. Any recovery by either Party as a result of any claim,
demand, litigation or other action contemplated by Section 7.1 or any settlement
thereof shall first be used to reimburse each Party for the reasonable costs of
the action borne by such Party (or, if the recovery is less than the aggregate
costs of such action, shall be distributed between the Parties in proportion to
the costs of the action borne by each of the Parties), with the remaining
amount, if any, to be paid to the Party bringing the action.

8.    TERM AND TERMINATION

      8.1   Term. The term of this Agreement shall be the Term as defined in
Article 1 unless terminated earlier than therein provided pursuant to this
Article 8.

      8.2   Termination for Cause. Each Party shall have the right to terminate
this Agreement at any time upon written notice to the other in the event (i) the
other Party is found in breach of any of its representations or fails to perform
any material obligation and such failure continues for a period of thirty (30)
days after notice thereof with respect to a payment failure or, with respect to
any other failure, such failure continues for a period of sixty (60) days after
notice thereof or (ii) the other Party is declared insolvent or bankrupt by a
court of competent jurisdiction, or a voluntary petition of bankruptcy is filed
in any court of competent jurisdiction by the other Party, or the other party
makes or executes any assignment for the benefit of creditors.

      8.3   Bankruptcy of Intellectual Property Proprietor. The Parties hereby
agree that licenses under this Agreement are licenses of intellectual property
as defined in Section 101(35A) (formerly Section 101(56)) of the Bankruptcy
Code, and that this license agreement is governed by Section 365(n) of the
Bankruptcy Code. Each party hereby agrees that in the event that its rights
under this Agreement are assigned to any non-Affiliate in connection with any
bankruptcy, insolvency or like proceeding involving it or its assets, such
assignee must assume all of its obligations under this Agreement.

9.    MISCELLANEOUS

      9.1   Payments. All payments due under this Agreement to either Party
shall be paid in U.S. Dollars. Exchange rates used to convert local currency to
U.S. Dollars shall be the month end exchange rates of New York banks for buying
U.S. dollars as published in the Wall Street Journal for the last month of the
quarter in respect of which payments are due.

      9.2   Taxes. All taxes due with respect to the manufacture of Products or
the marketing or sale of Kinetin C Products pursuant to Section 2.1.1shall be
paid by Vivier and all taxes due with respect to the marketing or sale of
Products pursuant to Section 2.1.2 shall be paid by Senetek or its licensees or
sub-licensees, except in either case for taxes due from and in respect of the
income of the other Party (an "Income Tax"). If either Party is required to
collect and remit any tax for which the other Party is responsible hereunder,
the remitting Party shall be

                                       16

<PAGE>

entitled to collect the amount of such tax from the Party responsible therefor
within 30 days of the date any such tax is remitted.

      9.3   No Joint Venture. It is not the intent of the Parties to form any
partnership or joint venture. Each Party shall, in relation to its obligations
hereunder, act as an independent contractor, and nothing in this Agreement shall
be construed to give either Party the power or authority to act for, bind or
commit the other.

      9.4   Governing Law. This Agreement shall be governed by and interpreted
in accordance with the laws of the State of California (regardless of that or
any other jurisdiction's choice of law principles).

      9.5   No Assignment. Neither Party may assign its rights or obligations
under this Agreement without the prior written consent of the other Party;
provided, however, that either Party may assign its rights to an Affiliate or to
any successor by merger, consolidation, sale of stock or the sale of
substantially all of the assets of such Party; provided further, that no such
permitted assignment shall relieve the assigning Party of its obligations under
this Agreement. Senetek and its Affiliates shall have the right to license third
parties to market and sell Products in accordance with Section 2.1.2, provided
that any such license and any sub-license thereunder shall require that the
licensee agree in writing to comply with the terms of this Agreement and shall
name Vivier as a third-party beneficiary with rights of enforcement.

      9.6   Force Majeure. This Agreement shall not be terminable by reason of,
and except as expressly provided in clauses (ii) and (iii) of Section 6.4, no
Party hereto shall be liable to the other for, any delay or default in such
Party's performance hereunder if such delay or default is caused by conditions
beyond such Party's control including, but not limited to, acts of God,
regulation or law or other action of any government or any agency thereof, war,
insurrection, civil commotion, destruction of production facilities or materials
by earthquake, fire, flood or storm, labor disturbances, epidemic, or failure of
suppliers, public utilities or common carriers. Each Party agrees to promptly
notify the other Party of any event of force majeure under this Section 9.6 and
to employ Best Efforts towards prompt resumption of its performance hereunder if
such performance is delayed or interrupted by reason of such event.

      9.7   Notices. Unless otherwise provided herein, any notice required or
permitted to be given hereunder (a "Notice") shall be mailed by certified mail
or generally recognized express courier service with signature required for
delivery, postage prepaid, sent by facsimile transmission, or delivered by hand
to the Party to whom such Notice is required or permitted to be given hereunder
at the address of such Party as first set forth above or at such other address
as the Party may furnish by Notice hereunder. If mailed, any such Notice shall
be deemed to have been given as of the date of receipt, as evidenced by the date
appearing on the delivery notice. If delivered by hand, any such Notice shall be
deemed to have been given when received by the Party or agent of such Party to
whom such Notice is given, as evidenced by written and dated receipt of the
receiving Party.

      9.8   Captions. The captions in this Agreement are solely for convenience
of reference and shall not be used for purposes of interpreting or construing
the provisions hereof.

                                       17

<PAGE>

      9.9   Severability. Should any part or provision of this Agreement be held
unenforceable or in conflict with the applicable laws or regulations of any
jurisdiction, the invalid or unenforceable part or provision shall be replaced
with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner,
and the remainder of this Agreement shall remain binding upon the parties
hereto.

      9.10  Waiver. No failure on the part of any party hereto to exercise, and
no delay in exercising, any right, privilege or power hereunder shall operate as
a waiver or relinquishment thereof; nor shall any single or partial exercise by
any Party hereto of any right, privilege or power hereunder preclude any other
or further exercise thereof, or the exercise of any other right, privilege or
power.

      9.11  Entire Agreement. This Agreement together with its Schedules
and Exhibits constitute the entire agreement and understanding between the
Parties with respect to the subject matter of this Agreement and shall supersede
any prior agreements, negotiations, understandings, representations, statements
and writings relating thereto. This Agreement may not be amended or modified
except in a writing signed by a duly authorized officer of the Party against
whom enforcement of such amendment is sought.

      9.12  Counterparts. This Agreement may be executed in one or more
counterparts by exchange of facsimile copies of signature pages, each of which
will be deemed an original and all of which together will constitute one and the
same instrument.

      9.13  Document Preparation. The Parties acknowledge that this Agreement is
a product of extensive negotiations and that no inference should be drawn
regarding the preparation of this document.

            IN WITNESS WHERE, the Parties have caused their duly authorized
representatives to execute this Agreement as of the Agreement Date.

                                       18

<PAGE>

                                      VIVIER PHARMA INC.

                                      By:
                                         ---------------------------------------

                                      Name:
                                           -------------------------------------

                                      Title:
                                            ------------------------------------

                                      SENETEK PLC

                                      By:
                                         ---------------------------------------

                                      Name:
                                           -------------------------------------

                                      Title:
                                            ------------------------------------

                                       19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]